R. Scott Struthers, Ph.D., is the President and Chief Executive Officer at Crinetics Pharmaceuticals Inc., a position he has held since the company's inception. Dr. Struthers has been instrumental in steering the company towards its mission of developing novel therapeutics for rare endocrine diseases and endocrine-related tumors. With a Ph.D. in Biochemistry from the University of California, Riverside, and extensive experience in the biopharmaceutical industry, Dr. Struthers has a deep understanding of drug discovery and development processes. Before founding Crinetics Pharmaceuticals, Dr. Struthers held key leadership positions at several prominent biopharmaceutical companies. He served as Senior Vice President of Biology at Neurocrine Biosciences, where he played a crucial role in the development of treatments for central nervous system disorders. Prior to that, he worked at Merck Research Laboratories, contributing to the development of several successful drugs. His expertise in endocrinology and neuroendocrinology, combined with his leadership skills, has been vital in guiding Crinetics Pharmaceuticals through its growth and development phases. As President and CEO of Crinetics Pharmaceuticals, Dr. Struthers oversees the strategic direction of the company, focusing on advancing its pipeline of innovative treatments. Under his leadership, the company has made significant progress in clinical trials and has secured substantial funding to support its research and development efforts. Dr. Struthers is committed to improving the lives of patients with rare endocrine disorders, and his vision continues to drive the company's success in this specialized field.